GlassScriptPhysician profile
Donald K Gaddy
NPI 1659358869
$1,547.35
in general payments reported to CMS, 2019-2025
29 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $90.67 · 2021: $39.33 · 2022: $378 · 2023: $126 · 2024: $209 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $210.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.30 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $127.85 | 2024-2025 | |
| Abbvie INC. | $126.79 | 2020-2023 | |
| Urovant Sciences INC | $114.28 | 2022 | |
| Myovant Sciences INC. | $75.55 | 2021-2022 | |
| Evofem Biosciences, INC. | $70.24 | 2023-2024 | Phexxi |
| Organon LLC | $69.59 | 2022-2024 | Nexplanon |
| Hologic Sales and Service, LLC | $62.70 | 2020 | |
| Daiichi Sankyo INC. | $52.79 | 2024 | Injectafer |
| Astellas Pharma US INC | $46.26 | 2023-2024 | Veozah |
| Mallinckrodt Enterprises LLC | $45.88 | 2019 | |
| Millicent US INC | $40.43 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Coloplast Corp | $40.01 | 2025 | |
| Therapeuticsmd, INC. | $39.06 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $33.72 | 2023-2024 | Myfembree, Gemtesa |
| Channel Medsystems, INC. | $30.51 | 2025 | |
| Merck Sharp & Dohme LLC | $30.33 | 2019-2020 | |
| Medtronic, INC. | $28.08 | 2025 | Truclear |
| Lsi Solutions INC | $26.25 | 2021 | |
| Smith+Nephew, INC. | $22.13 | 2022 | |
| Mayne Pharma Commercial LLC | $20.91 | 2024 | |
| Baxter Healthcare | $20.83 | 2025 | Perclot |
| Coopersurgical, INC. | $20.49 | 2025 | Paragard T 380a |
| Avanos Medical | $17.83 | 2025 | On-Q Pump and Accessories |
| Roche Diagnostics Corporation | $16.55 | 2019 | |
| Pfizer INC. | $14.59 | 2025 | |
| Meditrina | $3.79 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Gaddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.